« Intervention Delivered By Nurses Can Help Combat Depression In Cancer Patients | Main | Total Antidepressant Prescriptions Rise By 16 Million, USA »
Targacept Starts Phase 2b Clinical Trial Of TC-5214 As Augmentation Treatment In Major Depressive Disorder
By Depressed Jane | July 23, 2008
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that it has initiated a Phase 2b clinical trial of TC-5214 as an augmentation therapy in subjects with Major Depressive Disorder (MDD). TC-5214 is a broad spectrum neuronal nicotinic receptor (NNR) antagonist and represents a promising new mechanism in development for the treatment of MDD.
Topics: A Depressed Life |